Luminex Corporation announced the full commercial launch of FLEXMAP 3D system. FLEXMAP 3D multiplexing system allows scientists to simultaneously perform up to 500 tests on a single sample.
FLEXMAP 3D was designed to meet the needs of academic, reference and pharmaceutical research laboratories. The system will enhance the efficiencies of life sciences research and drug discovery by conducting many tests at time .
“We’re very excited about the full market launch of FLEXMAP 3D. This system was created for scientists who were seeking a faster throughput instrument with higher multiplexing capability. It will fill a vital need in high-volume laboratories and allow scientists to significantly increase their productivity,” said Patrick J. Balthrop, Sr., president and chief executive officer of Luminex. “FLEXMAP 3D is an important advancement in our goal to create multiplexing solutions for a range of applications and for laboratories of all sizes.”
FLEXMAP 3D using flexible xMAP Technology fills the segment between the low multiplex marketplace and the high multiplex microarray market. FLEXMAP 3D provides Scientists with improved analytical performance, higher multiplexing, enhanced dual pipetting, automation and LIS compatibility.
Multiplexed genomic, transcriptomic, and proteomic biomarker analysis on a single platform is performed by FLEXMAP 3D. FLEXMAP 3D is best suited for applications such as SNP genotyping and gene expression analysis. Faster screening of novel targets with overall improvement in laboratory management is provided by FLEXMAP 3D.
Luminex shipped a number of the FLEXMAP 3D systems to pharmaceutical and research laboratories since the first commercial shipment in November 2008.